CIPDB › China Industry › Chemicals › Pharmaceutical Intermediate
Anti Hair Loss CAS 38304-91-5 Minoxidil Powder Minoxidil1
Pharmaceutical IntermediateMinoxidilMinoxidil Powder
Xi'an Sase Biotechnology Co., Ltd
Preview:
Product DescriptionAnti Hair Loss CAS 38304-91-5 Minoxidil Powder MinoxidilProduct DescriptionProduct DetailsProduct NameMinoxidilCAS No.38304-91-5MFC9H15N5OMW209.24800AppearanceWhite PowderMinoxidil is a piperidinopyrimidine derivative with the chemical name 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide. This white to off-white crystalline powder has a molecular weight of 209.25 g/mol and exhibits solubility in water (approximately 2.2 mg/mL at 25°C) and better solubility in organic solvents like ethanol and glycol. The compound crystallizes in a monoclinic crystal system, with characteristic needle-like morphology observable under microscopy. Minoxidil shows UV absorption maxima at 230 nm and 280 nm in solution, with distinctive infrared spectroscopy peaks at 1550 cm1 (N-oxide stretch) and 3400 cm1 (amine groups). High-performance liquid chromatography analysis typically reveals purity levels exceeding 99%, with strict specifications for related substances including minoxidil N-oxide and other synthetic intermediates. The substance meets stringent pharmacopeial requirements for heavy metal content (<10 ppm) and residual solvents (<500 ppm), making it suitable for pharmaceutical applications. Thermal analysis demonstrates a melting point range of 248-252°C with decomposition, reflecting its stable heterocyclic structure. Minoxidil remains chemically stable under normal storage conditions but may undergo photodegradation upon prolonged light exposure, necessitating protection from ultraviolet radiation.Application&FunctionMinoxidil functions as a potent vasodilator and potassium channel opener, originally developed as an antihypertensive medication but now primarily used for treating androgenetic alopecia. Its mechanism of action involves direct stimulation of hair follicles through prolongation of the anagen phase and increased cutaneous blood flow. Clinical applications include topical solutions (2-5% concentration) for male and female pattern hair loss, with twice-daily application showing significant hair regrowth after 4-6 months of continuous use. The drug demonstrates particular efficacy in vertex baldness, with newer foam formulations improving patient compliance through reduced irritation. Recent applications explore oral minoxidil (0.25-5 mg daily) for refractory alopecia cases, though this requires careful monitoring for systemic effects. Safety studies indicate excellent topical tolerability, with common adverse effects limited to local irritation and hypertrichosis in some patients. Current research investigates its potential in other dermatological conditions including lichen planopilaris and chemotherapy-induced alopecia. Formulation development focuses on enhanced delivery systems like nanoparticles and microneedle arrays to improve follicular penetration. Pharmacovigilance data continue to support its favorable benefit-risk profile, with ongoing clinical trials evaluating optimal dosing regimens and combination therapies with other hair growth promoters. The substance's dual action as both a peripheral vasodilator and hair growth stimulant maintains its position as a first-line treatment for pattern hair loss worldwide.Specification
Purchasing Agent
Note: Send your message to supplier or manufacturer.
Welcome to our Professional and comprehensive procurement services...